Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6370773 | 0.81 | DYRK1A (0.44) | TGFBR1SCN5ADYRK1APCSK9 | |
| SCHEMBL23869389 | 0.75 | DYRK1A (0.43) | TGFBR1SCN5ADYRK1APCSK9 | |
| SCHEMBL30512173 | 0.74 | DYRK1A (0.47) | TGFBR1SCN5ADYRK1APDE10APCSK9 | |
| SCHEMBL1499196 | 0.73 | RBP4 (0.40) | TGFBR1SCN5APDE10ARBP4 | |
| SCHEMBL20190372 | 0.73 | SCN5A (0.68) | TGFBR1SCN5ADYRK1AALDH1A1 | |
| SCHEMBL18005343 | 0.73 | TGFBR1 (1.00) | TGFBR1SCN5ADYRK1A | |
| SCHEMBL14881931 | 0.72 | TGFBR1 (0.56) | TGFBR1SCN5ADYRK1ANOTUMALDH1A1 | |
| SCHEMBL1440869 | 0.71 | DYRK1A (0.49) | TGFBR1SCN5ADYRK1APDE10APCSK9 | |
| SCHEMBL1348540 | 0.70 | KDM4E (0.64) | TGFBR1SCN5ADYRK1AGABRA1GABRG2 | |
| SCHEMBL405358 | 0.69 | DYRK1A (0.47) | TGFBR1SCN5ADYRK1APDE10APCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235020-A1 | PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS | Wyeth LLC (US) | 2010-10-06 | — | — | EP | claimed |
| WO-2009086129-A1 | PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | claimed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| CN-118005640-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-111918651-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| EP-3746075-A1 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| EP-2523552-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011087999-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-7514443-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080051421-A1 | Pyrazolo-pyridine | WICHMANN JUERGEN | 2008-02-28 | — | — | US | disclosed |
| US-7329662-B2 | Pyrazolo-pyridine | HOFFMANN-LA ROCHE INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050130992-A1 | Pyrazolo-pyridine | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130992-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | TGFBR1 4432/4885SCN5A 867/4885DYRK1A 1407/4885 |
| US-20080051421-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | TGFBR1 4432/4885SCN5A 867/4885DYRK1A 1407/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | TGFBR1 4779/4885SCN5A 3839/4885DYRK1A 4540/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | TGFBR1 4251/4885SCN5A 3745/4885DYRK1A 1956/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | TGFBR1 4779/4885SCN5A 3839/4885DYRK1A 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.